论文部分内容阅读
胃癌是严重危害人类健康的恶性肿瘤之一,环氧合酶-2参与胃癌的发生发展过程,与胃癌的分化程度、浸润转移以及预后有着密切的联系。近年来,应用选择性COX-2抑制剂防治包括胃癌在内的各种恶性肿瘤的研究成为了肿瘤防治中的一大热点。选择性COX-2抑制剂能够通过COX-2依赖或非COX-2依赖的多种不同途径抑制胃癌细胞的增殖、诱导分化和凋亡、调节促癌基因与抑癌基因的平衡以及抑制肿瘤的新生血管的生成等机制控制胃癌的发生和进展。由于近期研究认为选择性COX-2抑制剂长期应用有诱发严重心血管事件的风险,其临床研究产生部分争议,进一步深入开展对选择性COX-2抑制剂的基础和临床研究可能有利于正确揭示上述存在的问题,为选择性COX-2抑制剂真正应用于临床胃癌防治奠定基础。
Gastric cancer is one of the malignant tumors that seriously endanger human health. Cyclooxygenase-2 is involved in the development and progression of gastric cancer, which is closely related to the differentiation, metastasis and prognosis of gastric cancer. In recent years, the application of selective COX-2 inhibitors in the prevention and treatment of various malignancies, including gastric cancer has become a hot topic in cancer prevention and treatment. Selective COX-2 inhibitors can inhibit gastric cancer cell proliferation, induce differentiation and apoptosis, regulate the balance of oncogenes and tumor suppressor genes, and inhibit tumor growth through a variety of different pathways that are COX-2 dependent or non-COX-2 dependent Neovascularization and other mechanisms to control the occurrence and progression of gastric cancer. As recent studies suggest that long-term use of selective COX-2 inhibitors poses a risk of triggering serious cardiovascular events, there is some controversy in its clinical studies, and further development of basic and clinical studies of selective COX-2 inhibitors may be beneficial in revealing correctly The above problems, for the selective use of COX-2 inhibitors for clinical prevention and treatment of gastric cancer lay the foundation.